Research programme: aurora kinase inhibitors - AstraZeneca

Drug Profile

Research programme: aurora kinase inhibitors - AstraZeneca

Alternative Names: Compound 677; ZM 447439

Latest Information Update: 22 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Quinazolines
  • Mechanism of Action Aurora kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Haematological malignancies

Most Recent Events

  • 16 Jan 2006 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route)
  • 16 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the Cancer pharmacodynamics section
  • 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top